Royalty Pharma (NASDAQ:RPRX) Stock: Insider Terrance Coyne Sells 232,536 Shares

Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) CFO Terrance Coyne sold 232,536 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $68.87, for a total transaction of $16,014,754.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock opened at $67.72 on Friday. Royalty Pharma PLC has a 52 week low of $37.31 and a 52 week high of $70.37. The stock has a market capitalization of $38.84 billion, a price-to-earnings ratio of 56.43, a PEG ratio of 1.36 and a beta of 0.37. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.29 and a current ratio of 1.29. The firm has a fifty day moving average of $62.11 and a two-hundred day moving average of $55.08.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $0.2350 per share. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. Royalty Pharma’s dividend payout ratio is 78.33%.

Institutional Trading of Royalty Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. DGS Capital Management LLC raised its holdings in shares of Royalty Pharma by 8.6% during the third quarter. DGS Capital Management LLC now owns 7,991 shares of the biopharmaceutical company’s stock worth $466,000 after purchasing an additional 632 shares during the period. Coastal Bridge Advisors LLC purchased a new stake in Royalty Pharma during the third quarter valued at about $329,000. Kentucky Retirement Systems Insurance Trust Fund boosted its position in shares of Royalty Pharma by 4.7% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 10,542 shares of the biopharmaceutical company’s stock worth $615,000 after buying an additional 471 shares during the period. Kentucky Retirement Systems grew its position in Royalty Pharma by 7.3% during the third quarter. Kentucky Retirement Systems now owns 26,046 shares of the biopharmaceutical company’s stock valued at $1,520,000 after purchasing an additional 1,777 shares in the last quarter. Finally, Regal Partners Ltd raised its stake in shares of Royalty Pharma by 2.9% during the 3rd quarter. Regal Partners Ltd now owns 2,519,922 shares of the biopharmaceutical company’s stock worth $147,063,000 after purchasing an additional 72,043 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on RPRX shares. TD Cowen lifted their target price on shares of Royalty Pharma from $68.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday. Bank of America restated a “buy” rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 14th. Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. Finally, Zacks Research raised Royalty Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 11th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat, Royalty Pharma has an average rating of “Buy” and a consensus price target of $65.00.

View Our Latest Analysis on RPRX

About Royalty Pharma

(Get Free Report)

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.

Featured Articles

Insider Buying and Selling by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.